HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
HCWainwright & Co. 重申買入ligand pharmaceuticals, 維持144美元的價格目標
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $144 price target.
HC Wainwright & Co.分析師Joseph Pantginis重申買入ligand pharmaceuticals(納斯達克:LGND),並維持144美元的目標價格。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。